Download the full-sized PDF
Permanent link (DOI): https://doi.org/10.7939/R3057D589
This file is in the following communities:
|Pediatrics, Department of|
This file is in the following collections:
D-Penicillamine for preventing retinopathy of prematurity in preterm infants Open Access
- Author or creator
Qureshi Mosarrat J.
- Additional contributors
Randomized Controlled Trials as Topic
Retinopathy of Prematurity
- Type of item
- Journal Article (Published)
Background The rate of retinopathy of prematurity (ROP) in moderately premature infants has decreased dramatically with improved care in the neonatal intensive care unit. A low rate of this disorder was unexpectedly observed among infants treated with intravenous D-penicillamine to prevent hyperbilirubinaemia. This observation led to the investigation of its use, both enterally as well as intravenously, to prevent ROP. Objectives To determine the effect of prophylactic administration of D-penicillamine on the incidence of acute ROP or severe ROP and other morbidities in preterm infants. Search methods We used the Cochrane Neonatal Review Group search strategy. Two review authors independently searched multiple electronic databases, previous reviews including cross references, abstracts, conference/symposia proceedings, and expert informants. We updated the search on November 27, 2012. Selection criteria We included randomised or quasi-randomised controlled trials if they administered D-penicillamine and compared it with no treatment or placebo to premature infants and reported on the outcome of ROP. Data collection and analysis We used the criteria and standard methods of the Cochrane Neonatal Review Group to assess the methodological quality of the included trials. One review author examined trials for validity. A second review author checked validity and they reached consensus on the final data before entry into this review. We used the standards of the Neonatal Cochrane Review Group to analyse data. Main results Three randomised trials met the inclusion criteria. The meta-analysis showed no significant differences in the risk of any stage ROP (typical risk ratio (RR) 0.32, 95% confidence interval (CI) 0.03 to 3.70), severe ROP (typical RR 0.38, 95% CI 0.03 to 4.26) or death (typical RR 0.95, 95% CI 0.68 to 1.32) in all treated infants. When the subgroup of infants under 1500 g birth weight was examined, the results were similar. No side effects were reported, and follow-up at one year revealed no significant differences in spasticity or developmental delay. Authors' conclusions Administration of prophylactic D-penicillamine in preterm infants does not prevent acute or severe ROP, death or neurodevelopmental delay. D-penicillamine cannot be recommended for the prevention of ROP based on the available evidence.
- Date created
- License information
- © 2013 QureshiMosarrat J. et al. This version of this article is open access and can be downloaded and shared. The original author(s) and source must be cited.
- Citation for previous publication
Qureshi Mosarrat J., Q., and Kumar Manoj, K. (2013). D-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database of Systematic Reviews, 2013(9), 1-29.
- Link to related item
- Date Uploaded
- Date Modified
- Audit Status
- Audits have not yet been run on this file.
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 469532
Last modified: 2017:09:05 16:32:01-06:00
Original checksum: 2a0d0c5bac92df337a34d49385f2b0de
Well formed: true
File title: /CT/CochraneCMS/TexRendering5/3488758.dvi
Page count: 31